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Appropriate Use Criteria
to Reduce Underuse and
Overuse of Revascularization
Although the appropriate use criteria (AUC) for the performance
of revascularization are well meaning, important limitations in-
clude the facts that they: 1) represent the consensus of a limited
group of stakeholders; 2) classify a minority of possible permuta-
tions of patient scenarios; 3) do not incorporate essential data
points, including specific lesion characteristics, extent of myocar-
dium supplied, fractional flow reserve and intravascular ultrasound
data, and important comorbidities (diabetes mellitus, chronic
kidney disease, and so forth); 4) are based on data recording in the
National Cardiovascular Data Registry by persons with widely
variable training and motivation without systematic monitoring,
adjudication, or audit; 5) undervalue quality of life issues, and in
this regard, ignore patient preferences; and 6) do not emphasize
underuse of percutaneous coronary intervention (1–4).
In this regard, Ko et al. (5) report that almost one-third of
ubjects undergoing angiography in Ontario, Canada, between
pril 2006 and March 2007 deemed “appropriate” by U.S. AUC
riteria were not revascularized. Such patients experienced appre-
iably worse clinical outcomes (increased incidence of death or
cute coronary syndrome presentation) through 3-year follow-up
hazard ratio [HR] of revascularization vs. medical therapy: 0.61;
5% confidence interval [CI]: 0.42 to 0.88). In the accompanying
ditorial, Patel (6) states: “This reduction in clinical events was not
een in patients with a revascularization classification (appropri-
teness score) of uncertain (HR: 0.57; 95% CI: 0.28 to 1.16) or
nappropriate (HR: 0.99; 95% CI: 0.48 to 2.02)” (6).
Although we agree with Dr. Patel regarding the apparent lack of
enefit associated with revascularization (vs. medical therapy) in
ubjects scored as inappropriate (at least as regards death or new
cute coronary syndrome, although chronic angina and quality of
ife data were not collected), we disagree with the conclusion for
he “uncertain” patients. Given the point estimate and confidence
nterval, this may well represent type II error. As evident from the
early identical HRs, the magnitude of benefit provided by
evascularization (vs. medical therapy) may be at least as great
mong the “uncertain” and “appropriate” classified cohorts, but was
bscured by the relative lack of power (only 326 subjects classified
s uncertain vs. 991 subjects classified as appropriate). Upsizing the
ncertain cohort to 991 subjects, with proportionally similar event
ates for revascularized (8%; 43 events) and medically treated(15.3%; 70 events) subjects, results in an odds ratio for revascular-
ization (vs. medical therapy) of 0.48 (95% CI: 0.31 to 0.73), a
highly statistically significant difference. Thus, on the basis of this
report, larger studies are warranted to determine whether the
spectrum of patients benefitting from revascularization should
expand to include the uncertain group (which would further
enlarge the specter of underuse).
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Reply
We appreciate the insightful comments provided by Drs. Kere-
iakes and Stone on our study (1). Applying the appropriate use
criteria of coronary revascularization on patients with stable coro-
nary artery disease afforded new insights on the potential overuti-
lization, underutilization, and uncertain use of coronary revascu-
larization in contemporary practice (2). In our population-based
cohort assembled in Ontario, Canada, we observed the majority
(68%) of coronary revascularizations were considered appropriate,
18% were considered uncertain, and 14% were considered inap-
propriate. Among patients who had appropriate indications, we
found that coronary revascularization was associated with a 39%
lower hazard of adjusted death or repeat acute coronary syndrome
at 3 years. We also observed that 31% of patients in the appropriate
category did not receive revascularization, suggesting that under-
utilization of therapy is still prevalent in clinical practice. In
contrast, patients who had inappropriate indications and received
coronary revascularization or medical therapy had no significant
difference in hazard of death or acute coronary syndrome, suggest-
ing potential overutilization of coronary revascularization in this
subgroup. Finally, many clinical scenarios in the appropriateness
